相关实验视频

Updated: Jun 25, 2025

Isolation, Expansion, and Adipogenic Induction of CD34+CD31+ Endothelial Cells from Human Omental and Subcutaneous Adipose Tissue

Isolation, Expansion, and Adipogenic Induction of CD34+CD31+ Endothelial Cells from Human Omental and Subcutaneous Adipose Tissue

Published on: July 17, 2018

用ATS-9R/siCcl2复合物向脂肪组织巨细胞的寡类策略,以改善GDM中的胰岛素抵抗

Min Wang¹, Xuyang Chen², Yanshan Shang¹

¹Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; The Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases, Chongqing Medical University, Chongqing 400016, China; State Key Laboratory of Maternal and Fetal Medicine of Chongqing, Chongqing Medical University, Chongqing 400016, China.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|May 22, 2024

概括

向脂肪组织巨细胞中的CCL2可以治疗妊娠糖尿病 (GDM). 一种新型的寡复合物减少了GDM模型中的炎症和胰岛素抵抗,显示出作为GDM治疗的潜力.

科学领域:

免疫学免疫学免疫学
代谢障碍代谢障碍代谢障碍
分子生物学分子生物学

背景情况:

孕期糖尿病 (GDM) 在治疗方法中提出了挑战.
CCL2是一种化学基因,与GDM病变发生有关.
在GDM中脂肪组织巨细胞 (ATM) 中CCL2的确切作用需要进一步研究.

研究的目的:

阐明GDM期间ATM中CCL2的机制.
评估在GDM中准CCL2的治疗潜力.

主要方法:

从GDM患者和小鼠的内脏脂肪组织中分析CCL2表达的分析.
在体外和体内实验中涉及Ccl2沉默的实验.
开发和测试ATS-9R/siCcl2寡复合物用于向脂肪组织的输送.

主要成果:

在GDM受试者的ATM中发现CCL2被丰富了.
通过调节运输和反应性氧物种 (ROS) 生成,巨细胞中的Ccl2沉默减少了炎症.
在GDM模型中,ATS-9R/siCcl2复合物有效地将Ccl2siRNA输送到ATM,减少脂肪组织炎症并改善胰岛素抵抗.

结论:

CCL2在与GDM相关的巨细胞炎症中起着重要作用.
通过减少胰岛素抵抗和炎症,ATS-9R/siCcl2寡复合体显示出作为针对性治疗GDM的潜力.

关键词:

脂肪组织的巨细胞在CCL2中,我们可以使用CCL2.在GDM中,GDM是GDM.炎症炎症是一种炎症.胰岛素耐药性胰岛素耐药性是一种有针对性的基因传递.

更多相关视频

Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots

Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots

Published on: June 2, 2015

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Published on: May 19, 2023

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...